SCHEMBL4263303

SCHEMBL4263303

CC(C)C(Br)c1nc2cc3ccccc3cc2c(=O)n1Cc1ccccc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.42
RAB9A P51151 2/20 0.42
LMNA P02545 1/20 0.42
RECQL P46063 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CACNA2D1 P54289 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TDP1 Q9NUW8 1/20 0.41
CYP2C19 P33261 2/20 0.41
MAP1LC3B Q9GZQ8 1/20 0.41
CYP3A4 P08684 1/20 0.41
KIF11 P52732 1/20 0.41
KCNH2 Q12809 1/20 0.41
GAA P10253 2/20 0.41
PDE4A P27815 1/20 0.41
PDE4B Q07343 1/20 0.41
PDE4C Q08493 1/20 0.41
PDE4D Q08499 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6026954 0.88 ALDH1A1 (0.56) ALDH1A1RAB9ALMNARECQLSMN1; SMN2
SCHEMBL6026713 0.86 ALDH1A1 (0.51) ALDH1A1POLB
SCHEMBL4517998 0.86 KIF11 (0.54) ALDH1A1RAB9ALMNARECQLSMN1; SMN2
SCHEMBL14078137 0.83 ADORA3 (0.43) ALDH1A1RAB9ALMNARECQLSMN1; SMN2
SCHEMBL14078131 0.82 CFTR (0.43) ALDH1A1RAB9ALMNARECQLSMN1; SMN2
SCHEMBL4320409 0.81 ALDH1A1 (0.45) ALDH1A1RAB9ALMNARECQLSMN1; SMN2
SCHEMBL14522639 0.79 PDE4A (0.57) ALDH1A1RAB9ALMNARECQLSMN1; SMN2
SCHEMBL4109641 0.79 ALDH1A1 (0.41) ALDH1A1RAB9ALMNARECQLSMN1; SMN2
SCHEMBL14367276 0.79 PDE4A (0.57) ALDH1A1RAB9ALMNARECQLSMN1; SMN2
SCHEMBL4091105 0.78 PDE4A (0.51) ALDH1A1RAB9ALMNARECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
US-20090214529-A9 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2009-08-27 US disclosed
WO-2008147852-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-12-04 WO disclosed
WO-2008147852-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-12-04 WO disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed
US-20080292626-A1 KINESIN INHIBITORS TAIGEN BIOTECHNOLOGY CO., LTD. (TW) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090214529-A9 KINESIN INHIBITORS KIF5B, KIF5A, KIF5C ALDH1A1 1978/4885RAB9A 388/4885LMNA 3815/4885
US-20080292626-A1 KINESIN INHIBITORS KIF5B, KIF5A, KIF5C ALDH1A1 1978/4885RAB9A 388/4885LMNA 3815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.